MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.
New York—On the eve of Pfizer’s annual shareholder meeting, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today hand-delivered to Pfizer headquarters the names of more than 400,000 people from 170 countries who signed a petition demanding that pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) reduce the price of the pneumonia vaccine to $5 per child in all developing countries and for humanitarian organizations.
Despite there being a vaccine that can prevent it, pneumonia remains the leading global cause of childhood death in many developing countries, killing almost one million kids each year. “Millions of babies and young kids around the world are left unprotected against pneumonia because Pfizer and GSK charge such high prices for the pneumonia vaccine that many governments and humanitarian organizations can’t afford to vaccinate children,” said Dr. Greg Elder, medical coordinator at MSF’s Access Campaign. “After combined sales of more than $30 billion for the pneumonia vaccine alone, we think it’s pretty safe to say that Pfizer and GSK can afford to lower the price so all developing countries can protect their children from this childhood killer.”
MSF delivered the petition outside Pfizer’s global headquarters in New York, where dozens of people placed flowers at the company’s door. One flower was laid in an empty baby crib for every child lost to pneumonia each day, resulting in 2,500 flowers. The names of people who signed MSF’s "A FAIR SHOT" petition are written on the crib.
The petition urges the two companies making the pneumonia vaccine to drop the price to $5 per child (for all three doses). With Pfizer having earned more than $6 billion in sales for this vaccine just last year alone, signatories of the petition sent a strong signal to Pfizer’s CEO, board and shareholders that the company should not put billions of dollars in profits over children’s lives, MSF said.
Last year, 193 governments at the World Health Assembly unanimously passed a landmark resolution demanding more affordable vaccines and increased transparency around vaccine prices. The governments of more than 50 countries underlined the rising inequities among them caused by the increased financial burden of new vaccines, with many stating that the high price of new vaccines, such as the pneumonia vaccine, either prohibited them from introducing it or threatened their ability to maintain it in their routine immunization programs.
Countries such as Algeria, Bosnia, Egypt, Indonesia, Jordan, Thailand, and Tunisia, among others, have expressed that they are not able to introduce the pneumonia vaccine because of its high price.
MSF has used the pneumonia vaccine in emergencies such as the Central African Republic, Ethiopia, South Sudan, Uganda and other countries. After more than five years of struggling to get Pfizer and GSK to sell the vaccine to MSF at an affordable price, MSF last year launched its "A FAIR SHOT" campaign to push the companies to reduce the price of the pneumonia vaccine to $5 per child.
In 2015, MSF released its vaccine pricing report, The Right Shot: Bringing Down Barriers to Affordable and Adapted Vaccines, which showed that in the poorest countries it is now 68 times more expensive to vaccinate a child than in 2001, with many parts of the world unable to afford new high-priced vaccines like that against pneumonia.
“We’ve seen too many children die of pneumonia, and we’re not going to stop until we know that all countries can afford this life-saving vaccine,” Elder said. “It’s tremendous to see that more than 400,000 people globally have joined us to tell Pfizer and GSK they must drop the price so more kids’ lives can be saved. What’s the point of a life-saving vaccine if the most vulnerable people can’t afford it?”
Each year, MSF teams vaccinate millions of people, both as outbreak response to diseases such as measles, meningitis, yellow fever and cholera, as well as routine immunization activities in projects where it provides health care to mothers and children. In 2014 alone, MSF delivered more than 3.9 million doses of vaccines and immunological products. MSF has purchased the pneumonia vaccine in the past for use in its emergency operations.
MSF is scaling up its use of the pneumonia and other vaccines with a particular focus on improving its work in routine immunization, as well as extending the package of vaccines used in humanitarian emergencies.